Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    May 2017
  1. RADHAKRISHNAN A, Grande D, Mitra N, Bekelman J, et al
    Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
    Cancer. 2017;123:1027-1034.
    PubMed     Text format     Abstract available


    April 2017
  2. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
    Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
    PubMed     Text format     Abstract available


    March 2017
  3. HURWITZ MD, Harris J, Sartor O, Xiao Y, et al
    Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30620.
    PubMed     Text format     Abstract available


  4. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30574.
    PubMed     Text format     Abstract available



  5. Erratum: Activation of nuclear factor kappaB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer.
    Cancer. 2017;123:892-893.
    PubMed     Text format    


    February 2017
  6. ARMSTRONG AJ, Saad F, Phung, Dmuchowski C, et al
    Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30587.
    PubMed     Text format     Abstract available


  7. PETTERSSON A, Gerke T, Fall K, Pawitan Y, et al
    The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.
    Cancer. 2017 Feb 2. doi: 10.1002/cncr.30582.
    PubMed     Text format     Abstract available


    January 2017
  8. LAI WS, Gordetsky JB, Thomas JV, Nix JW, et al
    Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30548.
    PubMed     Text format     Abstract available


  9. KIM H, Kalchman I, Santiago-Jimenez M, Lehrer J, et al
    Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30580.
    PubMed     Text format     Abstract available


  10. WILLIAMS SB, Huo J, Chamie K, Smaldone MC, et al
    Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.
    Cancer. 2017 Jan 18. doi: 10.1002/cncr.30506.
    PubMed     Text format     Abstract available


  11. BERNARD B, Muralidhar V, Chen YH, Sridhar SS, et al
    Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30503.
    PubMed     Text format     Abstract available


  12. PRINTZ C
    Smokeless tobacco product may increase mortality rate in patients with prostate cancer.
    Cancer. 2017;123:190.
    PubMed     Text format    


    December 2016
  13. KLAASSEN Z, Howard LE, de Hoedt A, Amling CL, et al
    Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30505.
    PubMed     Text format     Abstract available


  14. DESS RT, Jackson WC, Suy S, Soni PD, et al
    Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
    Cancer. 2016 Dec 21. doi: 10.1002/cncr.30519.
    PubMed     Text format     Abstract available


  15. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    PubMed     Text format    


  16. PINSKY PF, Prorok PC, Yu K, Kramer BS, et al
    Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30474.
    PubMed     Text format     Abstract available


    November 2016
  17. CHEN RC
    Lymph node-positive prostate cancer-From middle child to the new frontier.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30374.
    PubMed     Text format    


  18. JEGADEESH N, Liu Y, Zhang C, Zhong J, et al
    The role of adjuvant radiotherapy in pathologically lymph node positive prostate cancer.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30373.
    PubMed     Text format     Abstract available


  19. FRANCINI E, Taplin ME
    Prostate cancer: Developing novel approaches to castration-sensitive disease.
    Cancer. 2016 Nov 1. doi: 10.1002/cncr.30329.
    PubMed     Text format     Abstract available


    September 2016
  20. KEARNS JT, Gore JL
    Prostate cancer screening: Do guidelines matter?
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30331.
    PubMed     Text format    


  21. REKOSKE BT, McNeel DG
    Immunotherapy for prostate cancer: False promises or true hope?
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30250.
    PubMed     Text format     Abstract available


  22. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


  23. HOLMES JA, Bensen JT, Mohler JL, Song L, et al
    Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30315.
    PubMed     Text format     Abstract available


  24. ALIBHAI SM, Timilshina N, Duff-Canning S, Breunis H, et al
    Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30320.
    PubMed     Text format     Abstract available


    August 2016
  25. WHITNEY CA, Howard LE, Amling CL, Aronson WJ, et al
    Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
    Cancer. 2016 Aug 9. doi: 10.1002/cncr.30221.
    PubMed     Text format     Abstract available


  26. KOVTUN KA, Chen MH, Braccioforte MH, Moran BJ, et al
    Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Cancer. 2016 Aug 4. doi: 10.1002/cncr.30224.
    PubMed     Text format     Abstract available


    July 2016
  27. CARLSSON SV, de Carvalho TM, Roobol MJ, Hugosson J, et al
    Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30192.
    PubMed     Text format     Abstract available


  28. MAHAL BA, Chen YW, Muralidhar V, Mahal AR, et al
    National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30205.
    PubMed     Text format     Abstract available


  29. TURNER AR, Lane BR, Rogers D, Lipkus I, et al
    Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30162.
    PubMed     Text format     Abstract available


  30. JACOBS BL, Lopa SH, Yabes JG, Nelson JB, et al
    Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
    Cancer. 2016 Jul 5. doi: 10.1002/cncr.30184.
    PubMed     Text format     Abstract available


    June 2016
  31. WANG K, Sheets NC, Basak R, Chen RC, et al
    Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30154.
    PubMed     Text format     Abstract available


  32. KASUYA G, Ishikawa H, Tsuji H, Nomiya T, et al
    Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30050.
    PubMed     Text format     Abstract available


    May 2016
  33. HALPERN JA, Sedrakyan A, Hsu WC, Mao J, et al
    Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Cancer. 2016 May 25. doi: 10.1002/cncr.30101.
    PubMed     Text format     Abstract available


  34. MCPARTLIN AJ, Glicksman R, Pintilie M, Tsuji D, et al
    PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    Cancer. 2016 May 24. doi: 10.1002/cncr.30093.
    PubMed     Text format     Abstract available


  35. FALCHOOK AD, Basak R, Mohiuddin JJ, Chen RC, et al
    Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30049.
    PubMed     Text format     Abstract available


  36. KEANE FK, D'Amico AV
    Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30048.
    PubMed     Text format    


  37. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Text format     Abstract available


  38. BAKER BR, Basak R, Mohiuddin JJ, Chen RC, et al
    Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30034.
    PubMed     Text format     Abstract available


  39. PRICE DK, Chau CH, Till C, Goodman PJ, et al
    Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Cancer. 2016 May 10. doi: 10.1002/cncr.30071.
    PubMed     Text format     Abstract available


  40. SHUI IM, Wong CJ, Zhao S, Kolb S, et al
    Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30045.
    PubMed     Text format     Abstract available


    March 2016
  41. VIANI GA, Viana BS, Martin JE, Rossi BT, et al
    Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29983.
    PubMed     Text format     Abstract available


  42. CHOW H, Ghosh PM, deVere White R, Evans CP, et al
    A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29927.
    PubMed     Text format     Abstract available



  43. Erratum: Long-term quality of life among Dutch prostate cancer survivors.
    Cancer. 2016;122:974.
    PubMed     Text format    


  44. PRINTZ C
    Early-stage prostate cancer, PSA screening rates decline.
    Cancer. 2016;122:825.
    PubMed     Text format    


  45. MAHAL BA, Chen YW, Efstathiou JA, Muralidhar V, et al
    National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.
    Cancer. 2016 Mar 11. doi: 10.1002/cncr.29960.
    PubMed     Text format     Abstract available


  46. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


  47. WRIGHT BJ, Conlin AK, Allen HL, Tsui J, et al
    What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
    Cancer. 2016;122:791-7.
    PubMed     Text format     Abstract available


    February 2016
  48. DESAUTELS D, Czaykowski P, Nugent Z, Demers AA, et al
    Risk of colorectal cancer after the diagnosis of prostate cancer: A population-based study.
    Cancer. 2016 Feb 25. doi: 10.1002/cncr.29919.
    PubMed     Text format     Abstract available


  49. PRINTZ C
    Racial difference seen in outcomes for older patients with prostate cancer.
    Cancer. 2016;122:501.
    PubMed     Text format    


  50. SANYAL C, Aprikian AG, Cury FL, Chevalier S, et al
    Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29892.
    PubMed     Text format     Abstract available


  51. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


    January 2016
  52. FILSON CP, Natarajan S, Margolis DJ, Huang J, et al
    Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
    Cancer. 2016 Jan 7. doi: 10.1002/cncr.29874.
    PubMed     Text format     Abstract available


    December 2015

  53. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P and Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortalit
    Cancer. 2015;121:4272.
    PubMed     Text format    



  54. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R and Freedland SJ. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study.
    Cancer. 2015;121:4271.
    PubMed     Text format    


    November 2015
  55. PRINTZ C
    Treatment improves for localized prostate cancer.
    Cancer. 2015;121:3929.
    PubMed     Text format    


  56. NYROP KA, Deal AM, Williams GR, Guerard EJ, et al
    Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29786.
    PubMed     Text format     Abstract available


  57. FILSON CP, Shelton JB, Tan HJ, Kwan L, et al
    Expectant management of veterans with early-stage prostate cancer.
    Cancer. 2015 Nov 5. doi: 10.1002/cncr.29785.
    PubMed     Text format     Abstract available


  58. LAVIANA AA, Ilg AM, Veruttipong D, Tan HJ, et al
    Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
    Cancer. 2015 Nov 2. doi: 10.1002/cncr.29743.
    PubMed     Text format     Abstract available


    October 2015
  59. HANYOK BT, Howard LE, Amling CL, Aronson WJ, et al
    Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Cancer. 2015 Oct 20. doi: 10.1002/cncr.29748.
    PubMed     Text format     Abstract available


    September 2015

  60. Erratum: Buffart LM, Newton RU, Chinapaw MJ, Taaffe DR, Spry NA, Denham JW, Joseph DJ, Lamb DS, Brug J and Galvao DA. The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivo
    Cancer. 2015;121:3367-3368.
    PubMed     Text format    


  61. DONOVAN KA, Walker LM, Wassersug RJ, Thompson LM, et al
    Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.
    Cancer. 2015 Sep 15. doi: 10.1002/cncr.29672.
    PubMed     Text format     Abstract available


  62. MAHAL BA, Aizer AA, Efstathiou JA, Nguyen PL, et al
    Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.
    Cancer. 2015 Sep 15. doi: 10.1002/cncr.29691.
    PubMed     Text format     Abstract available


  63. DREYFUS M, Wion D
    Investigating the relationship between vitamin D and cancer requires dosing the bioavailable nonhydroxylated vitamin D storage in cancer tissues.
    Cancer. 2015;121:3362-3.
    PubMed     Text format    


  64. SHUI IM, Giovannucci E
    Reply to investigating the relationship between vitamin d and cancer requires dosing the bioavailable nonhydroxylated vitamin d storage in cancer tissues.
    Cancer. 2015;121:3363-4.
    PubMed     Text format    


  65. YANEZ B, McGinty HL, Mohr DC, Begale MJ, et al
    Feasibility, acceptability, and preliminary efficacy of a technology-assisted psychosocial intervention for racially diverse men with advanced prostate cancer.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29658.
    PubMed     Text format     Abstract available


    August 2015
  66. CHAMIE K, Williams SB, Hershman DL, Wright JD, et al
    Population-based assessment of determining predictors for quality of prostate cancer surveillance.
    Cancer. 2015 Aug 26. doi: 10.1002/cncr.29574.
    PubMed     Text format     Abstract available


  67. MERDAN S, Tomlins SA, Barnett CL, Morgan TM, et al
    Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Cancer. 2015 Aug 17. doi: 10.1002/cncr.29611.
    PubMed     Text format     Abstract available


    July 2015
  68. RATHKOPF DE, Larson SM, Anand A, Morris MJ, et al
    Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
    Cancer. 2015 Jul 15. doi: 10.1002/cncr.29578.
    PubMed     Text format     Abstract available


  69. LEE WR
    Seduced by technology?
    Cancer. 2015;121:2300-2.
    PubMed     Text format    


  70. REICHERT ZR, Hussain MH
    Addressing apoptosis to tumor zip codes.
    Cancer. 2015;121:2296-9.
    PubMed     Text format    


  71. ALIBHAI SM, Breunis H, Timilshina N, Naglie G, et al
    Long-term impact of androgen-deprivation therapy on physical function and quality of life.
    Cancer. 2015;121:2350-7.
    PubMed     Text format     Abstract available


  72. ALIBHAI SM, O'Neill ME
    Comorbidity and the risk of venous thromboembolism in prostate cancer.
    Cancer. 2015 Jul 6. doi: 10.1002/cncr.29536.
    PubMed     Text format    


  73. ORDING AG, Horvath-Puho E, Lash TL, Ehrenstein V, et al
    Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995-2011.
    Cancer. 2015 Jul 6. doi: 10.1002/cncr.29535.
    PubMed     Text format     Abstract available


  74. REICHARD CA, Stephenson AJ, Klein EA
    Applying precision medicine to the active surveillance of prostate cancer.
    Cancer. 2015 Jul 6. doi: 10.1002/cncr.29496.
    PubMed     Text format     Abstract available


    May 2015
  75. WANG LS, Murphy CT, Ruth K, Zaorsky NG, et al
    Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer.
    Cancer. 2015 May 29. doi: 10.1002/cncr.29472.
    PubMed     Text format     Abstract available


  76. TWARDOWSKI P, Kanaya N, Frankel P, Synold T, et al
    A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.
    Cancer. 2015 May 18. doi: 10.1002/cncr.29421.
    PubMed     Text format     Abstract available


  77. SAVARD J, Ivers H, Savard MH, Morin CM, et al
    Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study.
    Cancer. 2015;121:1703-11.
    PubMed     Text format     Abstract available


  78. PAL SK, Agarwal N, Jones JO
    Circulating tumor cells in prostate cancer: Does (nuclear) size matter?
    Cancer. 2015 May 14. doi: 10.1002/cncr.29454.
    PubMed     Text format    


  79. CHEN JF, Ho H, Lichterman J, Lu YT, et al
    Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.
    Cancer. 2015 May 14. doi: 10.1002/cncr.29455.
    PubMed     Text format     Abstract available


    April 2015
  80. PINHEIRO LC, Wheeler SB, Chen RC, Mayer DK, et al
    The effects of cancer and racial disparities in health-related quality of life among older Americans: a case-control, population-based study.
    Cancer. 2015;121:1312-20.
    PubMed     Text format     Abstract available


  81. DELOUGHERY TG, Beer TM
    Bevicizumab and thrombosis: some answers but questions remain.
    Cancer. 2015;121:975-7.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: